Insider Buying: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Purchases 76,140 Shares of Company Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker bought 76,140 shares of the stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average cost of $384.32 per share, with a total value of $29,262,124.80. Following the completion of the purchase, the director directly owned 2,040,682 shares in the company, valued at $784,274,906.24. This represents a 3.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker purchased 15,666 shares of Madrigal Pharmaceuticals stock. The stock was bought at an average cost of $367.71 per share, for a total transaction of $5,760,544.86.

Madrigal Pharmaceuticals Stock Down 0.1%

MDGL stock traded down $0.47 during mid-day trading on Friday, reaching $399.63. The company had a trading volume of 1,087,445 shares, compared to its average volume of 352,856. The firm has a fifty day simple moving average of $489.63 and a 200 day simple moving average of $497.94. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.94 and a current ratio of 3.05. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $353.54 and a fifty-two week high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. The business had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. During the same period in the previous year, the company posted ($5.08) earnings per share. Analysts forecast that Madrigal Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Citigroup boosted their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a research note on Tuesday. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price on the stock in a report on Tuesday, August 4th. HC Wainwright started coverage on Madrigal Pharmaceuticals in a report on Wednesday. They issued a “strong-buy” rating on the stock. Finally, UBS Group reaffirmed a “buy” rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $706.87.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Institutional Trading of Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. J. Goldman & Co LP acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $2,722,000. Royal Bank of Canada grew its holdings in Madrigal Pharmaceuticals by 22.5% during the first quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company’s stock worth $6,557,000 after acquiring an additional 2,303 shares during the period. Hsbc Holdings PLC grew its holdings in Madrigal Pharmaceuticals by 1,738.3% during the second quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company’s stock worth $10,868,000 after acquiring an additional 19,139 shares during the period. Sivik Global Healthcare LLC acquired a new position in Madrigal Pharmaceuticals during the third quarter worth $1,260,000. Finally, Legal & General Group Plc purchased a new position in Madrigal Pharmaceuticals in the second quarter worth $6,630,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.